Moxifloxacin-containing Regimens of Reduced Duration Produce a Stable Cure in Murine Tuberculosis
| Autor: | Ian M. Rosenthal, Tetsuyuki Yoshimatsu, Kathy N. Williams, Richard E. Chaisson, Jacques H. Grosset, Richard J. O'Brien, William R. Bishai, Andrew Vernon, Eric L. Nuermberger, Sandeep Tyagi |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Tuberculosis Combination therapy Moxifloxacin Antitubercular Agents Pharmacology Critical Care and Intensive Care Medicine Sensitivity and Specificity Gastroenterology Drug Administration Schedule Mice Random Allocation Reference Values Intensive care Internal medicine medicine Animals Tuberculosis Pulmonary Antibacterial agent Aza Compounds Mice Inbred BALB C Dose-Response Relationship Drug business.industry Isoniazid biochemical phenomena metabolism and nutrition Pyrazinamide bacterial infections and mycoses medicine.disease Disease Models Animal Regimen Multivariate Analysis Quinolines Drug Therapy Combination Female business Fluoroquinolones medicine.drug |
| Zdroj: | American Journal of Respiratory and Critical Care Medicine. 170:1131-1134 |
| ISSN: | 1535-4970 1073-449X |
| DOI: | 10.1164/rccm.200407-885oc |
| Popis: | In a recent experimental study using the mouse model of tuberculosis, treatment with a combination of rifampin, moxifloxacin, and pyrazinamide was able to shorten the time to negative lung cultures by up to 2 months compared with the standard regimen of rifampin, isoniazid, and pyrazinamide. To confirm that this substitution of moxifloxacin for isoniazid permits a shorter duration of treatment, a second study was performed in which mice were assessed for relapse after treatment with combination therapy for 3, 4, 5, or 6 months. Although no relapse was observed among mice treated for at least 4 months with rifampin, moxifloxacin, and pyrazinamide, mice treated with rifampin, isoniazid, and pyrazinamide required 6 months of treatment before no relapse could be detected. For mice treated with rifampin, moxifloxacin, and pyrazinamide, similar efficacy was noted whether pyrazinamide was administered for 1 month, 2 months, or the entire duration of therapy. These results suggest that the use of rifampin, moxifloxacin, and pyrazinamide may substantially shorten the duration of therapy needed to cure human tuberculosis and that the full benefit of pyrazinamide in this regimen may be realized after just 1 month of treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|